Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience.
about
Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert RecommendationsReview article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trialEarly anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factorsAnti-inflammatory effects of novel AP-1 and NF-κB inhibitors in dextran-sulfate-sodium-induced colitis in rats.Inflammatory bowel disease in Chinese children: A retrospective analysis of 49 cases.An update of the role of nutritional therapy in the management of Crohn's disease.The vagal innervation of the gut and immune homeostasisReview article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis.Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy?TNF blocking therapies and immunomonitoring in patients with inflammatory bowel diseaseInflammatory bowel disease meta-evidence and its challenges: is it time to restructure surgical research?Asia-Pacific consensus statements on Crohn's disease. Part 2: Management.Development of a conceptual model evaluating the humanistic and economic burden of Crohn's disease: implications for patient-reported outcomes measurement and economic evaluation.Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines.Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease.Short-term outcomes of laparoscopic surgery for Crohn's disease patients treated with anti-tumor necrosis factor alpha agents.Complications in surgery for Crohn's disease after preoperative antitumour necrosis factor therapy.Colonic perforation in a child with Crohn's disease: successful medical treatment rescues from colectomyWhy could passive Immunoglobulin E antibody therapy be safe in clinical oncology?Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment.Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.Infliximab-induced thrombocytopenia in an elderly patient with ileocolonic Crohn's disease.Serum protein profile of Crohn's disease treated with infliximab.Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease.Quantitative bottom up analysis of infliximab in serum using protein A purification and integrated μLC-electrospray chip IonKey MS/MS technology.Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease.
P2860
Q28087015-B5956BE4-DC66-43A9-85DC-531720E9B69EQ33410771-E9F44129-93D5-4C8E-AB44-C5F7923351ACQ34767921-1941EADB-E0A3-44BB-9750-5874FB7D31DBQ36380315-EE29DBF7-1CDE-4B6E-8BAF-7D84D1A503BCQ36901080-10FC18DC-9F44-4B66-A4C1-40F8F4A1BB8DQ37406598-0F6A99E9-FF71-4874-AFA2-5D6EB4D8236DQ38018812-E75E7B7D-7185-4CA4-B6BE-319DA8DABCBEQ38047774-C3C77AEE-9E46-49D0-AC4D-D954D10316F7Q38121115-86EEB29F-0647-4737-9FF6-2A7D606BCB1FQ38122070-D2674258-6E27-4304-89C3-79DC4132BA0DQ38191334-FD57CF47-0DEF-45E0-BAB4-2220BBB823DBQ38206507-75E5AA90-4A80-4537-8DA7-83B2ABAC3A3EQ38302725-210B3E43-D367-449A-8B0B-FD05DFFBEE38Q38394726-5F35B41E-8A10-4D36-9190-9BBAC1712B38Q38488635-98929FBF-BC16-4FD1-8D34-F8CC31E049BAQ38596171-6F9E565C-35BF-4674-B932-8DD3F4B97BF8Q38622923-59E6A818-60D3-440A-B0CF-621701A6DA53Q39636883-375DCC0D-0037-42C3-8705-E94666C5FBB1Q42224687-45B1B9B6-C906-4560-BBD5-53F4B368BFD7Q42471409-3BBE114F-35AA-4235-BEB9-F3AB37E5DBF4Q42558684-12E4A7BC-5995-49A5-BA4A-2D88704A535BQ43567807-5A4563A8-00B8-4330-A3C3-6E556C5A5CFEQ45083749-D7A881EE-0A3D-4AF7-BE60-3068A129E8A4Q45827766-4B3A4765-79B3-4956-A4D1-C0ADF5A5750AQ45886414-307D1CF6-141C-4EC5-A2EB-53F4BE05EC00Q50555814-553E33A8-400C-4EC2-B54A-84373F69B91AQ50870630-522B9F5D-BE95-467E-ADEB-4081C814974AQ51052885-F1F0D3EB-38F3-484D-A15A-B4BE38481738Q51376286-B2A370DB-0C91-4EB5-BA6D-CE43156CFF8AQ53813065-0F976846-1FAB-4D7D-92BE-C39CCBDA9557
P2860
Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Review article: infliximab for ...... years of clinical experience.
@en
Review article: infliximab for ...... years of clinical experience.
@nl
type
label
Review article: infliximab for ...... years of clinical experience.
@en
Review article: infliximab for ...... years of clinical experience.
@nl
prefLabel
Review article: infliximab for ...... years of clinical experience.
@en
Review article: infliximab for ...... years of clinical experience.
@nl
P2093
P2860
P1476
Review article: infliximab for ...... years of clinical experience.
@en
P2093
J-F Colombel
P J Rutgeerts
W Reinisch
P2860
P304
P356
10.1111/J.1365-2036.2011.04598.X
P407
P577
2011-02-15T00:00:00Z